5 recruiting. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 5 |
| Phase 1 | 1 | Recruiting 1 |
Follow Focal Segmental Glomerulosclerosis: new trials by email Literature Review of Focal Segmental Glomerulosclerosis trials Research Report on Focal Segmental Glomerulosclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases ManNAc - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | National Human Genome Research Institute (NHGRI) | 30 | 2026-10-27 | 2026-10-30 |
| A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) Praliciguat (Part A), Placebo (Part A), Praliciguat (Part B) - Focal Segmental Glomerulosclerosis | Phase 2 | Recruiting | Akebia Therapeutics | 60 | 2025-12-03 | 2026-10-01 |
| A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease frexalimab, brivekimig, rilzabrutinib - Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion | Phase 2 | Recruiting | Sanofi | 84 | 2024-12-19 | 2026-10-19 |
| AMPK-activation by Metformin in FSGS: AMP-FSGS Metformin + Standard of Care, Placebo + Standard of Care - Focal Segmental Glomerulosclerosis | Phase 1 / Phase 2 | Recruiting | Yale University | 30 | 2023-12-14 | 2026-02-03 |
| Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases Sparsentan - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | Travere Therapeutics, Inc. | 67 | 2021-08-12 | 2026-05-12 |
Glomerulosclerosis, Focal Segmental (5) · Nephrosis, Lipoid (3) · Macular dystrophy, corneal type 1 (2) · Proteinuria (2) · Glomerulonephritis, IGA (1) · Glomerulonephritis, Membranous (1) · IgA Vasculitis (1) · Kidney Diseases (1) · Nephritis, Hereditary (1) · Renal Insufficiency, Chronic (1)
Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Glomerulonephritis (5) · Male Urogenital Diseases (5) · Nephritis (5) · Urogenital Diseases (5) · Urologic Diseases (5) · Kidney Diseases (4) · Nephrosis (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Autoimmune Diseases (2) · Immune System Diseases (2) · Pathologic Processes (2) · Urination Disorders (2)
Metformin (1) · N-acetylmannosamine (1) · Standard of Care (1) · praliciguat (1) · sparsentan (1)
Akebia Therapeutics (1) · National Human Genome Research Institute (NHGRI) (1) · Sanofi (1) · Travere Therapeutics, Inc. (1) · Yale University (1)
United States (5) · Germany (2) · Italy (2) · Netherlands (2) · Poland (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · Chile (1) · China (1) · Czechia (1) · France (1)
Cijiang He (1) · Madhav Menon, MD (1) · Radko Komers, MD, PhD (1) · William A Gahl, M.D. (1)
PMID 38724717, PMID 39899371, PMID 40938675, PMID 41630898, PMID 42384439